| CPC A01N 63/50 (2020.01) [A01H 5/10 (2013.01); A01N 37/46 (2013.01); A01P 1/00 (2021.08); A01P 3/00 (2021.08); A61P 31/10 (2018.01); C07K 14/4723 (2013.01); C12N 15/8282 (2013.01); A61K 38/00 (2013.01)] | 21 Claims |
|
1. An antifungal peptide comprising a modified C-terminal plant defensin peptide wherein:
(i) the unmodified C terminal plant defensin peptide comprises from N-terminus to C-terminus the conserved amino acid sequence GXCX3-10(C)(X)(C) (SEQ ID NO: 592) and a conserved cysteine residue located at the C-terminus of the unmodified C terminal plant defensin peptide;
(ii) the conserved amino acid sequence GXCX3-10(C)(X)(C) (SEQ ID NO: 592) of the unmodified C terminal plant defensin peptide is replaced with a modified gamma-core consensus sequence GXCX3-10(F/W/Y)(F/W/Y)(F/W/Y) (SEQ ID NO: 587) in the modified C-terminal plant defensin peptide;
(iii) the modified C-terminal plant defensin peptide retains the conserved cysteine residue located at the C-terminus of the unmodified C terminal plant defensin peptide;
(iv) the modified C-terminal plant defensin peptide has a net positive charge of at least 3 at neutral pH and a hydrophobic amino acid content at least 18%, wherein the hydrophobic amino acids are alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; and
(v) the modified C-terminal plant defensin peptide exhibits antifungal activity.
|